Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph L Kuti

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Pharmacotherapy|July 1, 2024
Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organismsChristina Koenig, Joseph L Kuti
Expert Opinion on Drug Metabolism & Toxicology|February 14, 2023
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modelingYuwei Shen, Joseph L Kuti
Expert Opinion on Drug Metabolism & Toxicology|September 9, 2010
Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infectionsEffie L Kuti, Joseph L Kuti
International Journal of Antimicrobial Agents|March 2, 2015
Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patientsJoseph L Kuti, David P Nicolau
The Canadian Journal of Hospital Pharmacy|July 13, 2016
Stability of Ertapenem 100 mg/mL at Room TemperatureJoseph L Kuti, David P Nicolau
Journal of Critical Care|March 2, 2010
Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathwayJoseph L Kuti, David P Nicolau
Chemotherapy|June 30, 2005
Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainmentJoseph L Kuti, David P Nicolau
Diagnostic Microbiology and Infectious Disease|December 20, 2005
Making the most of surveillance studies: summary of the OPTAMA ProgramJoseph L Kuti, David P Nicolau
Frontiers in Pharmacology|April 4, 2022
Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse <i>Versus</i> ManAngela V Berry, Joseph L Kuti
Mycoses|June 19, 2010
Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United StatesAryun Kim, David P Nicolau, Joseph L Kuti
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Pharmacotherapy|July 1, 2024
Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organismsChristina Koenig, Joseph L Kuti
Expert Opinion on Drug Metabolism & Toxicology|February 14, 2023
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modelingYuwei Shen, Joseph L Kuti
Expert Opinion on Drug Metabolism & Toxicology|September 9, 2010
Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infectionsEffie L Kuti, Joseph L Kuti
International Journal of Antimicrobial Agents|March 2, 2015
Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patientsJoseph L Kuti, David P Nicolau
The Canadian Journal of Hospital Pharmacy|July 13, 2016
Stability of Ertapenem 100 mg/mL at Room TemperatureJoseph L Kuti, David P Nicolau
Journal of Critical Care|March 2, 2010
Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathwayJoseph L Kuti, David P Nicolau
Chemotherapy|June 30, 2005
Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainmentJoseph L Kuti, David P Nicolau
Diagnostic Microbiology and Infectious Disease|December 20, 2005
Making the most of surveillance studies: summary of the OPTAMA ProgramJoseph L Kuti, David P Nicolau
Frontiers in Pharmacology|April 4, 2022
Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse <i>Versus</i> ManAngela V Berry, Joseph L Kuti
Mycoses|June 19, 2010
Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United StatesAryun Kim, David P Nicolau, Joseph L Kuti
Pageof 25